Convergent epitope-specific T cell responses after SARS-CoV-2 infection and vaccination

- 3 Anastasia A. Minervina^{1#}, Mikhail V. Pogorelyy^{1#}, Allison M. Kirk¹, E. Kaitlynn Allen¹, Kim J.
- 4 Allison², Chun-Yang Lin¹, David C. Brice¹, Xun Zhu³, Kasi Vegesana⁴, Gang Wu³, Jeremy Chase
- 5 Crawford¹, Stacey Schultz-Cherry², Jeremie H. Estepp⁵, Maureen A. McGargill¹, the SJTRC Study
- 6 Team*, Joshua Wolf², Paul G. Thomas¹
- 8 Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN USA
- 9 ² Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN USA
- 10 ³ Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN USA
- ⁴ Information Services, St. Jude Children's Research Hospital, Memphis, TN USA
- 12 ⁵ Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN
- 13 USA

14

22

25

26

27

1

2

- 15 #Equal contribution
- 16 Aditya Gaur, James Hoffman, Motomi Mori, Li Tang, Elaine Tuomanen, Richard Webby, Hana
- 17 Hakim, Randall T. Hayden, Diego R. Hijano, Resha Bajracharya, Walid Awad, Lee-Ann Van de
- 18 Velde, Brandi L Clark, Taylor L. Wilson, Robert C. Mettelman, Aisha Souquette, Ashley
- 19 Castellaw, Ronald H. Dallas, Jason Hodges, Ashleigh Gowen, Jamie Russell-Bell, James Sparks,
- 20 David E. Wittman, Thomas P. Fabrizio, Sean Cherry, Ericka Kirkpatrick Roubidoux, Valerie
- 21 Cortez, Pamela Freiden, Nicholas Wohlgemuth, Kendall Whitt;
- 23 Correspondence to Joshua Wolf joshua.wolf@stjude.org and Paul Thomas
- paul.thomas@stjude.org
 - Abstract
- 28 SARS-CoV-2 mRNA vaccines, including Pfizer/Biontech BNT162b2, were shown to be effective
- 29 for COVID-19 prevention, eliciting both robust antibody responses in naive individuals and
- 30 boosting pre-existing antibody levels in SARS-CoV-2-recovered individuals. However, the
- 31 magnitude, repertoire, and phenotype of epitope-specific T cell responses to this vaccine, and the

effect of vaccination on pre-existing T cell memory in SARS-CoV-2 convalescent patients, are still poorly understood. Thus, in this study we compared epitope-specific T cells elicited after natural SARS-CoV-2 infection, and vaccination of both naive and recovered individuals. We collected peripheral blood mononuclear cells before and after BNT162b2 vaccination and used pools of 18 DNA-barcoded MHC-class I multimers, combined with scRNAseq and scTCRseq, to characterize T cell responses to several immunodominant epitopes, including a spike-derived epitope cross-reactive to common cold coronaviruses. Comparing responses after infection or vaccination, we found that T cells responding to spike-derived epitopes show similar magnitudes of response, memory phenotypes, TCR repertoire diversity, and αβTCR sequence motifs, demonstrating the potency of this vaccination platform. Importantly, in COVID-19-recovered individuals receiving the vaccine, pre-existing spike-specific memory cells showed both clonal expansion and a phenotypic shift towards more differentiated CCR7-CD45RA+ effector cells. Indepth analysis of T cell receptor repertoires demonstrates that both vaccination and infection elicit largely identical repertoires as measured by dominant TCR motifs and receptor breadth, indicating that BNT162b2 vaccination largely recapitulates T cell generation by infection for all critical parameters. Thus, BNT162b2 vaccination elicits potent spike-specific T cell responses in naive individuals and also triggers the recall T cell response in previously infected individuals, further boosting spike-specific responses but altering their differentiation state. Overall, our study demonstrates the potential of mRNA vaccines to induce, maintain, and shape T cell memory through vaccination and revaccination.

Introduction

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

The ongoing COVID-19 pandemic led to the rapid development of novel types of antiviral vaccines, including the mRNA-based Pfizer/Biontech BNT162b2 regimen. Vaccination with BNT162b2 elicits both antibody and T cell responses (Sahin et al. 2020). However, the magnitude of T cell responses in naive individuals following infection or vaccination as well as the effect of vaccination on pre-existing memory cells remains controversial (Camara et al. 2021; Thimme et al. 2021; Painter et al. 2021), in part because the very nature of the T cell response complicates its unbiased quantification. While antibodies bind antigen directly, and thus can be measured and compared among donors using universal assays, T cells recognize antigen presented on the cell

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

surface by the Major Histocompatibility Complex (MHC), which is encoded by the most polymorphic genes in the human population (Robinson et al. 2019). Variability of peptide-MHC across and within donors makes measuring epitope-specific T cell responses challenging, and as a result studies often rely on bulk response (e.g., peptide stimulation) assays. Although peptide stimulation assays in principle can provide an estimate of the total CD8 response, they underestimate the frequency of epitope-specific T cells (Sahin et al. 2021). Staining with MHCmultimers loaded with individual peptides is an alternative approach, but it requires pre-selection of immunogenic peptides. Several immunodominant SARS-CoV-2 epitopes presented by common HLA alleles were discovered in the past year, permitting the tracking of epitope-specific T cell response in infected (Francis et al. 2021; Gangaev et al. 2021; Schreibing et al. 2021; Shomuradova et al. 2020; Kared et al. 2021; Saini et al. 2021; Ferretti et al. 2020; Nielsen et al. 2021; Peng, Yanchun et al. 2020; Rha et al. 2021; Sekine et al. 2020; Schulien et al. 2021; Habel et al. 2020; Nguyen et al. 2021) and vaccinated (Thimme et al. 2021; Sahin et al. 2021) individuals using MHC-multimers. Although at the peak of the infection response reports have described more than 10% of CD8+ T cells specific to a single SARS-CoV-2 epitope (Saini et al. 2021; Gangaev et al. 2021), a month after infection the frequency of most epitope-specific T cell populations is typically less than 1% (Ferretti et al. 2020; Peng, Yanchun et al. 2020; Kared et al. 2021; Rha et al. 2021). The rapid expansion and subsequent contraction of the T cell response occur in both infection (Thevarajan et al. 2020) and vaccination (Thimme et al. 2021), and careful choice of sampling timepoints is important to compare the magnitude of T cell responses in different donors. The diversity of T cell phenotypes adds another layer of complexity as effector and memory subpopulations differ in longevity, cytotoxic potential, and cytokine production.

Most vaccines are currently given in early childhood and are assessed by serological measures. When vaccine-induced T cell responses have been measured in humans or model systems, they frequently have reduced magnitude or narrower repertoires compared to natural infection (Cukalac et al. 2009; 2014; Oberle et al. 2016; Cornberg et al. 2006; Malherbe et al. 2008). Therefore, to directly compare the T cell response following infection or mRNA vaccination in naive and recovered COVID-19 individuals, we combined DNA-barcoded MHC-multimer staining (specific for spike and non-spike protein-derived epitopes) with scRNAseq and scTCRseq to profile epitope-specific T cell responses. We identified epitope-specific T cell responses of comparable

magnitude and phenotype following infection or naive vaccination, with further expansion of spike-specific T cells after convalescent vaccination. Longitudinal sampling of SARS-CoV-2 recovered donors before and after vaccination allowed us to observe clonal expansions and phenotype shifts among spike-specific memory T cells. Although the durability of immune protection provided by natural infection and primary vaccination remains unknown, our data suggest that mRNA vaccination in naive donors induces largely equivalent spike-specific T cell responses as infection, while revaccination with a spike-specific mRNA vaccine in recovered subjects can boost both T cell and antibody responses.

Results

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

To investigate the ability of mRNA vaccines to trigger epitope-specific T cell responses as well as the effect of vaccination on memory T cells, we selected a cohort of 19 individuals from SJTRC, an ongoing prospective, longitudinal study of St. Jude Children's Research Hospital adult (≥18 years old) employees (Fig. 1A). Nine of these participants had never tested positive for COVID-19 during weekly PCR testing from the time SARS-CoV-2 reached the local area to time of sampling (naive, N1-N9), whereas 10 of the subjects were diagnosed as COVID-19 positive with a PCR test and recovered from mild disease (recovered, R1-R10) during the study period. Both the naive and recovered groups received two doses of the Pfizer-BioNTech BNT162b2 mRNA vaccine. Donors from each group were primarily chosen to ensure they were sampled at similar timepoints after the second dose of vaccine (R: 43±3.5; N: 46±3.5; Fig. S1A) and exhibited a similar distribution of HLA alleles of interest (Fig. S1B). PBMCs from recovered individuals were additionally obtained prior to the first vaccine dose ("post-infection" group, R1-R6), after the first dose (R7, R8, R10), or immediately subsequent to the second dose of vaccine (R9) (Fig. 1A). In concordance with previous reports (Goel et al. 2021; Krammer et al. 2021; Ebinger et al. 2021), we observed an anti-RBD (Fig. 1B) and anti-spike protein IgG (Fig. S2) boost after vaccination of recovered individuals. Two recovered individuals (R7 and R8) showed decreased RBD IgG postsecond dose compared to the post-first dose sampling, though the decreases were minimal. Although it is generally accepted that recovered individuals do not benefit from the second dose of the vaccine (Wang et al. 2021; Mazzoni et al. 2021; Krammer et al. 2021; Goel et al. 2021; Ebinger et al. 2021; Camara et al. 2021), donor R10 clearly exhibited antibody boost due to the

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

second dose of BNT162b2. Overall, anti-RBD (Fig. 1B inset) and anti-spike IgG levels (Fig. S2) were similar between recovered and naive groups after vaccination. As expected, SARS-CoV-2naive donors were negative for N-protein specific antibodies (Fig. S2), as only the S-protein is included in the vaccine. Thus, in both naive and recovered individuals, BNT162b2 vaccination induces high levels of anti-RBD and anti-spike IgG antibodies. To evaluate epitope-specific CD8 T cell responses to mRNA vaccination, we selected 18 SARS CoV-2 epitopes (6 from the S protein and 12 from other proteins) that have been previously described by us or others, are likely to elicit a T cell response, and are presented on the common HLA alleles A*01:01, A*02:01, A*24:02, B*15:01 and B*44:02 (Fig. 1C, Supplementary Table 1) (Tarke et al. 2021; Kared et al. 2021; Snyder et al. 2020; Gangaev et al. 2021; Schulien et al. 2021; Nelde et al. 2021; Ferretti et al. 2020; Shomuradova et al. 2020; Peng, Yanchun et al. 2020; Sekine et al. 2020). In addition, four of the epitopes (A24 VYI, B15 NQK, B44 AEV and B44 VEN) were highly similar to orthologs from common cold coronaviruses (CCCoV), and the CCCoV variant MHC-dextramers were also included to test the cross-reactive potential of these epitopes. PBMCs from each donor were stained with a panel of DNA-barcoded, fluorescently-labeled dextramers (Fig. 1A, Supplementary Table 2) that matched the donors' HLA alleles. For SARS-CoV-2-naive, vaccinated donors, these panels only included spike-derived MHC-dextramers. Epitope-specific T cells (CD3+CD8+dextramer+ cells) were isolated using FACS (Fig. S3) and then subjected to scRNAseq, scTCRseq, and CITEseq using the 10x Chromium platform. We obtained dextramer-positive CD8+ T cells from all naive, vaccinated donors and COVID-19 infected donors at convalescent timepoints and after vaccination, with varying frequencies. The overall frequency of dextramer-specific cells was quite low (0.23±0.05% of CD8+ T cells; range: 0.02-1% of CD8+ T cells), but matched expectations based on epitope-specific memory cells' frequencies observed months after the challenge in other studies (Ferretti et al. 2020; Peng, Yanchun et al. 2020; Kared et al. 2021; Rha et al. 2021). The absolute magnitude of epitopespecific T cell responses was similar across all groups (Fig. 1D) despite varying sources and episodes of antigen exposure.

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

Use of the DNA-barcoded dextramers allowed us to deconvolve the overall T cell response to 18 distinct epitope-specific responses. For each cell, we calculated the number of unique molecular identifiers (UMIs) per dextramer, and we considered a cell as dextramer-specific if more than 30% of the dextramer-derived UMIs corresponded to that dextramer's specific barcode. This resulted in non-overlapping dextramer-positive and -negative groups of cells for each dextramer (Fig. 2A, Fig. S4). To additionally test this threshold, we considered the dextramer assignment of individual cells among the 15 most abundant T cell clones (i.e., clone sizes \geq 12 cells) defined by scTCRseq. Eleven of the most abundant clonotypes matched a single specificity across all cells (Fig. 2B), indicating that the dextramer specificity thresholds were generally robust. Interestingly, three of the most abundant TCR clonotypes were assigned to both B15-NQK Q SARS-CoV-2 and B15-NQK A CCCoV (HKU1/OC43) orthologs of the spike epitope, supporting our initial hypothesis for potential SARS-CoV-2/CCCoV epitope cross-reactivity. Indeed, the UMI counts for the dextramers with SARS-CoV-2 and CCCoV variants of the epitope correlated strongly (Fig. 2C), suggesting that the exact same cells can bind both versions of the epitope. To further demonstrate that a single TCR can recognize both variants of B15-NOK, we made a Jurkat cell line expressing one of the potentially cross-reactive αβTCRs. This T cell line successfully recognized both CCCoV and SARS-CoV-2 variants of the peptide, as demonstrated by MHC-multimer staining (Fig. 2D) and peptide stimulation assays (Fig. S5). For 6 of 7 HLA-B*15 positive donors, we also measured antibody IgG levels against the spike protein of common cold betacoronaviruses HKU1 and OC43 prior to infection/vaccination. All of the donors except one had high titers of the antibodies (Fig. S6). Interestingly, the donor lacking antibodies to OC43/HKU1 also had the lowest T cell response to this epitope. These data indicate that SARS-CoV-2 may reactivate cross-reactive memory CD8+ T cells established during previous OC43/HKU1 infection. Because barcoded dextramers allow us to simultaneously measure the response to multiple epitopes in the same sample on the single-cell level, we also utilized these data to compare the magnitude of the response to different epitopes. These analyses established that the most immunodominant epitopes include A01 TTD, A01 LTD, A02 YLQ and B15 NQK (Fig. 2E). Importantly, these epitopes not only elicited the strongest response, but also were found in all HLA-matched samples. Although we observed responses to all other epitopes, they occurred at lower frequencies and only in a subset of HLA-matched donors. Epitopes A01_TTD, A24_NYN and A01_NTN are affected by mutations in SARS-CoV-2 variants of concern delta (P822L in the ORF1ab protein, L452R in the spike protein) and gamma (P80R in the N protein). However, models predicting peptide-MHC binding (NetMHCpan4.1b; (Reynisson et al. 2020)) suggest that these mutations do not impact the binding of the epitope to the restricting HLA allele, as both variants are predicted to be strong binders (Supplementary Table 3).

We next asked if we could identify signals corresponding to a T cell boost after the vaccination of SARS-CoV-2 recovered individuals. This can be difficult to resolve, as it requires accounting for clonal expansion of spike-specific T cells after vaccination and contraction of both spike- and non-spike-specific T cells following natural infection. The overall frequency of the spike-specific T cell response remained the same after vaccination, which is unsurprising given that the samples were obtained after memory formation. However, for the A02_YLQ spike epitope, we observed a trend towards a stronger T cell response in the context of vaccination (Fig. 2F). Although the overall frequency of epitope-specific cells may be the same before and after vaccination, or even decreasing after vaccination, the composition can shift due to the expansion of spike-specific clones (Fig. 2G, Fig. S7). Indeed, in 5 out of 6 donors, we observed an increase in the fraction of the spike-specific T cell response in comparison to the non-spike response after vaccination, indicating the recruitment of epitope-specific memory T cells among recovered individuals in the response to vaccination (Fig. 2H).

To understand if there are any differences in the phenotypes of epitope-specific T cells after natural infection, vaccination of naive, and vaccination of SARS-CoV-2 recovered individuals, we performed single cell gene expression (GEX) analysis. This analysis identified 8 distinct clusters of epitope-specific cells (Fig. 3A). According to the surface expression of conventional memory markers (CCR7 and CD45RA) measured by CITEseq (Fig. 3B) and other markers from scRNAseq (Fig 3C, Supplementary Table 4, Supplementary Table 5), the clusters were annotated as Effector Memory with expression of GZMK (EM-GZMK), EM with reexpression of CD45RA (EMRA), EM with exhaustion markers (EM-Ex), EM with high expression of mitochondrial genes (EM-Mito), Transitional memory (TM), naive/T stem cell-like memory, Cycling, and EM with GATA3.

Cells obtained either post-infection or post-vaccination were found across all gene expression clusters (Fig. S8, S9). Thus, natural infection, as well as vaccination, lead to the formation of potent T cell memory, including both highly cytotoxic populations and populations with expression of common markers of durable cellular memory, including TCF7, IL7R, and CCR7 (Fig. 3C).

218

219

220

221

222

223

224

225

226

227

228

229

230

231232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

To determine if a recall response during vaccination affects the phenotypes of T cells, we compared the GEX cluster distribution of recovered donors post-infection and post-vaccination. Epitope-specific T cells were present in all clusters before and after vaccination, independent of their specificity (Fig. 3D). However, we observed a significant post-vaccination shift towards a more highly differentiated effector phenotype (EMRA) of spike-specific cells, but not for non-spike-specific cells, suggesting that this shift was due to the involvement of spike-specific memory T cells in the recall response to vaccination in convalescent donors (Fig. 3E, (p=0.007, one-tailed Wilcoxon rank-sum test).

Recent publications have linked T cell exhaustion to more severe COVID-19 (Kusnadi et al. 2021; Zheng et al. 2020; Diao et al. 2020). Our epitope-specific data similarly included a cluster with high expression of classical exhaustion markers, including CTLA-4, PD-1, TOX, and TIGIT (Cluster 2, EM-Ex, Fig. 3C). Interestingly, this cluster was present only in a fraction of donors, but was present across all conditions: naive donor after vaccination (donors N3, N6, N9), postinfection (R1, R6), post-first dose in recovered donors (R7), and post-second dose in recovered donors (R4, R9). Thus, the appearance of this cluster was not connected to disease severity or the nature of the antigenic stimulus (vaccine or virus). In concordance with previous reports (Schreibing et al. 2021; Kusnadi et al. 2021), this cluster was composed of highly expanded clones (Fig. S10), with more than 87% of the cluster repertoire occupied by just 10 clones (Fig. 3F). We also observed that a cluster of exhausted cells was in close proximity in UMAP-space with a cluster of cycling cells with high expression of MKI67 and TUBB (Fig. 3A, Fig. 3C), indicating a possible connection between these two phenotypic states. Indeed, the number of cells in an exhausted cluster within a patient strongly correlated with the number of cells in the cluster of cycling cells (Fig. 3G). Thus, the presence of the exhausted cluster is connected to both clonal expansion and cell proliferation, suggesting that donors who have such cells are still in the active rather than memory state of immune response. If the "exhausted" cluster is indeed the feature of an active immune response state, it must be transient. To test this, we looked at the distribution of cells among clusters at two available timepoints for recovered individuals (average time between timepoints was 81 days, range 47-121). Almost all cells from this exhausted cluster were absent from the epitope-specific pool of memory T cells at the later timepoint (Fig. 3H). This was observed for both spike and non-spike-specific cells, indicating that the vaccine does not impact the survival of these "exhausted" cells.

The majority of the clonotypes in the exhausted cluster are highly expanded and are present among other clusters of memory T cells. While the majority of the "exhausted" T cells apparently die, the clonotype lineage and thus the specificity of T cell response is preserved in the EM and EMRA compartments (Fig. 3I). Importantly, the overall TCRβ repertoire diversity (represented by normalised Shannon entropy) is comparable between vaccinated naive donors, post-infection donors, and the post-infection/post-vaccination donors (Fig 3J), suggesting that a diverse repertoire of T cells persists in the memory compartment regardless of antigenic history. This is distinct from other models comparing vaccination to infection (Cukalac et al. 2009; Malherbe et al. 2008).

We and others have previously shown that T cells recognizing the same epitopes frequently have highly similar T cell receptor sequences (Glanville et al. 2017; Dash et al. 2017). In Fig. 4A, we plot a similarity network of paired unique αβTCR sequences from our data (Supplementary table 6), using a threshold on the TCRdist (Dash et al. 2017) similarity measure to identify highly similar clonotypes. The clusters of similar sequences almost exclusively consist of TCRs with the same epitope specificity and feature biases in V-segment usage (Fig. S11, S12) and strong preference for certain amino acid residues at certain positions of CDR3 region (Fig. 4B). Importantly, the same motifs in spike-specific TCRs were shared between donors who recovered from natural infection and immunologically naive donors after immunization (Fig. 4C). Furthermore, the most prevalent TCR sequence motif specific to A02_YLQ was present across all HLA-matched samples studied. This suggests that epitope recognition is achieved by the same TCR-pMHC molecular interactions, and thus one could expect similar specificity to potential epitope variants for memory T cells elicited by vaccination or natural infection.

Discussion

Vaccination was shown to be effective in preventing COVID-19, but durability of protection is yet to be determined. It is critical to understand if pre-existing SARS-CoV-2 immunity could be successfully boosted through vaccination. We show that the Pfizer/Biontech BNT162b2 vaccine boosts both antibody levels and T cells specific for SARS-CoV-2 spike protein in individuals with pre-existing immunity for natural infection. We also show that there is no profound difference in frequency, phenotype, or TCR motifs in memory T cells generated by natural infection and vaccination. Taken together, this suggests that mRNA vaccines would be also effective for boosting of pre-existing vaccine-induced immunity during revaccination. The direct comparison between infection- and vaccine-elicited T cell responses has not been well-studied previously in humans as most vaccines are given in very young children. The success of those vaccines also limits the population that acquire natural infection as a comparator group.

We also discovered T cells cross-reactive for SARS-CoV-2 and common cold coronavirus variants of an HLA*B15-restricted immunodominant epitope. The possibility of this cross-reactivity was hypothesized in (Minervina et al. 2021), where the clonotypes with this TCR motif were the most expanded in an HLA-B*15 positive donor. Francis et al. recently described HLA-B*07_SPR, another epitope from N-protein, as being cross-reactive with HKU1 and OC43 common-cold coronaviruses. The extent of protection in HLA-B*15 and HLA-B*07 positive donors recently infected with common cold coronaviruses is yet to be determined, but a high frequency of cross-reactive CD8 T cells may be a correlate of protection.

Using longitudinal sampling, we show that certain T cell populations, including differentiated effector cells with exhaustion markers or actively proliferating T cells, are transient and not found in the same donor at later timepoints. Expanded clones contributing to these transient clusters persist in other clusters with long lived memory phenotype. This result agrees with the functional experiment from Gangaev et al. who showed that a fraction of epitope specific T cells sampled close to acute infection timepoints are dysfunctional, but restore IFNgamma/TNFa production further into convalescence. The exhausted T cell phenotype was previously linked to more severe disease (Kusnadi et al. 2021; Zheng et al. 2020; Diao et al. 2020), but our data suggests that time

since immune stimulus (either infection or vaccination) could also explain the presence of these exhausted effectors. Given that many severe patients may have extended viral replication dynamics, their sampling may occur closer to recent antigen exposure. This does not preclude the accumulation of exhausted T cells as contributing to severe disease phenotypes, but it also might merely be a correlate of extended antigen exposure. Further, the presence of this exhausted phenotype in subjects with all forms of antigen exposure indicates that the presence of these cells is not sufficient to cause significant pathology.

An important limitation of our study is that we could not compare the effect of one vs two doses of mRNA vaccine in individuals with pre-existing immunity. It has been suggested in multiple studies that a second vaccine dose in individuals with pre-existing immunity does not further increase antibody levels from the first dose (Wang et al. 2021; Mazzoni et al. 2021; Krammer et al. 2021; Goel et al. 2021; Ebinger et al. 2021; Camara et al. 2021), but the effect on T cells remains to be studied. We found an increase in the fraction of EMRA T cells in fully vaccinated subjects with pre-existing immunity. Whether or not this increase is associated with more (or less) durable and efficient protection is not clear. Longer term follow-up studies of the durability of memory in vaccine-only, infection-only, and vaccinated after infection groups should closely monitor the phenotype of antigen-specific T cell responses.

Precise measurement of epitope-specific T cell and B cell responses is crucial for defining the correlates of SARS-CoV-2 protection, which will inform vaccination strategies to prevent pandemic recurrence as additional SARS-CoV-2 variants emerge. The striking similarity between the phenotypes and constituent repertoires of epitope-specific CD8 T cell responses following infection, vaccination, or infection followed by vaccination, indicate that mRNA vaccines are capable of inducing equivalent memory as an infection episode and further expanding these responses if previously established. These data further suggest that booster shots, if needed to address antibody-escape, will not substantially alter the repertoires of established anti-spike T cell memory. These data are a stark contrast to annual, non-adjuvanted split influenza vaccines, where repeated vaccination has raised some concerns of immune imprinting, tolerance, and reduced vaccine efficacy (Petrie and Monto 2017). While longer term comparative studies between

vaccinated and infected individuals are necessary, our results establish BN162b2 vaccination as a potent inducer of SARS-CoV-2 specific CD8 T cells with a profile equivalent to natural infection.

Methods

340

341

342343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

Human cohort

The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study (SJTRC, NCT04362995) is a prospective, longitudinal cohort study of St. Jude Children's Research Hospital adult (≥18 years old) employees. The St. Jude Institutional Review Board approved the study. Participants provided written informed consent prior to enrollment and then completed regular questionnaires about demographics, medical history, treatment, and symptoms if positively diagnosed by PCR with SARS-CoV-2. Study data are collected and managed using REDCap electronic data capture tools hosted at St. Jude (Harris et al. 2009; 2019). Participants were screened for SARS-CoV-2 infection by PCR approximately weekly when on St. Jude campus. For this study, we selected a cohort of 19 individuals, nine of which had never tested positive for COVID-19 (naive, N1-N9), and 10 of which were diagnosed as COVID-19 positive with a PCR test and recovered from mild disease (recovered, R1-R10) during the study period. All individuals in this study received two doses of the Pfizer-BioNTech BNT162b2 mRNA vaccine and, most importantly, were sampled at similar time points after their vaccine regimen was complete (Recovered: 43±3.5; Naive: 46±3.5; Fig. S1A). These individuals also expressed a similar distribution of HLA allele of interest (A01:01, A02:01, A24:02, B15:01, B44:02; Fig. S1B). Finally, the individuals chosen for each group were of similar ages (Recovered: 44.5±4.9 years; Naive: 42.7±3.5 years). For this study, we utilized the convalescent blood draw for SARS-CoV-2 infected individuals (3-8 weeks post diagnosis) and the post-vaccination samples for both SARS-CoV-2 convalescent and naive individuals (3-8 weeks after completion of the vaccine series). Blood samples were collected in 8 mL CPT tubes and separated within 24 hours of collection into cellular and plasma components and aliquoted and frozen for future analysis. Human cohort metadata can be found in the Supplementary Table 2.

HLA typing

High quality DNA was extracted from whole blood aliquots from each participant using the Zymo Quick-DNA 96 Plus Kit (Qiagen). DNA was quantified on the Nanodrop. HLA typing of each participant was performed using the AllType NGS 11-Loci Amplification Kit (One Lambda; Lot 013) according to manufacturer's instructions. Briefly, 50 ng DNA was amplified using the AllType NGS 11-Loci amplification primers, and the amplified product was cleaned and quantified on the Qubit 4.0 (Invitrogen). Library preparation of purified amplicons was carried out as described in the protocol, and the AllType NGS Index Flex Kit (Lot 011) was used for barcoding and secondary amplification. Purified, barcoded libraries were quantified using the Qubit DNA HS kit (Invitrogen) and pooled according to the One Lambda Library Pooling table. Pools of up to 48 libraries were then purified and then quantified on the TapeStation D5000 (Agilent) before sequencing on a full MiSeq lane at 150x150bp following manufacturer's sequencing specifications. HLA types were called using the TypeStream Visual Software from One Lambda. HLA typing results can be found in the Supplementary Table 2.

Variant of concern mutation analysis

We used the WHO definition of variant of concern and variant of interest updated July 6, 2021. A mutation was included in the analysis if it appears in at least 10% of the GISAID isolates with the same Pango lineage (Rambaut et al. 2020). To analyze the predicted binding of variant and wild type peptides we used NetMHCpan 4.1b (Reynisson et al. 2020). Results of this analysis are in Supplementary Table 3.

Dextramer generation and cell staining

Peptides with >95% purity were ordered from Genscript and diluted in DMSO to 1 mM. pMHC monomers (500 nM) were generated with easYmer HLA class I (A*01:01, A*02:01, A*24:02, B*15:01, B*44:02) kits (Immunaware) according to the manufacturer's protocol. To generate DNA-barcoded MHC-dextramers we used Klickmer technology (dCODE Klickmer, Immudex). 16.2 μL of HLA monomer (500 nM) were mixed with 2 μL barcoded dCODE-PE-dextramer to achieve an average occupancy of 15 and incubated for at least 1 hour on ice prior to use. Individual dextramer cocktails were prepared immediately before staining (Supplementary Table 2). Each cocktail had 1.5 μL of each HLA-compatible barcoded MHC-dextramer-PE and 0.15 μL 100 μM

biotin per dextramer pre-mixed to block free binding sites. Samples were divided into 3 batches, and timepoints from the same donor were always processed simultaneously. Donor PBMCs were thawed and resuspended in 50 µL FACS buffer (PBS, 0.5% BSA, 2 mM EDTA). Cells were stained with 5 µL Fc-block (Human TruStain FcX, Biolegend 422302) and a cocktail of dextramers for 15 minutes on ice. After this a cocktail of fluorescently-labeled surface antibodies (2 μL of each: Ghost Dye Violet 510 Viability Dye, Tonbo Biosciences 13-0870-T100; anti-human CD3 FITC-conjugated (Biolegend 300406, clone UCHT1), anti-human CD8 BV711-conjugated (Biolegend, 344734, clone SK1)) and TotalSeq-C antibodies (1 µL anti-human CCR7 (Biolegend 353251), 1 μL anti-human CD45RA (Biolegend 304163)) and 2 μL of TotalSeq-C anti-human Hashtag antibodies 1-10 (Biolegend 394661, 394663, 394665, 394667, 394669, 394671, 394673, 394675, 394677, 394679) were added. Samples were incubated for 30 minutes on ice. Single, Live, CD3-positive, CD8-positive, dextramer-positive cells were sorted into RPMI (Gibco) containing 10% FBS and 1% penicillin/streptomycin. Sorted cells were immediately loaded into a 10x reaction. Chromium Next GEM Single Cell 5' kits version 2 (10x Genomics PN: 1000265, 1000286, 1000250, 1000215, 1000252 1000190, 1000080) were used to generate GEX, VDJ and Cite-Seq libraries according to the manufacturer's protocol. Libraries were sequenced on Illumina NovaSeq at 26x90bp read length.

Single cell RNAseq data analysis

Raw data was processed with Cell Ranger version 6.0.0 (10X Genomics). Three batches were subsequently combined using the aggregate function with default parameters. Resulting GEX matrices were analysed with the Seurat R package version 3.2.3 (Stuart et al. 2019). Following standard quality control filtering, we discarded low quality cells (nFeatures<200 or over 5000, MT%>10%) and eliminated the effects of cell cycle heterogeneity using the CellCycleScoring and ScaleData functions. Next, we identified 2000 variable gene features. Importantly, we discarded TCR/Ig genes from variable features, so that the gene expression clustering would be unaffected by T cell clonotype distributions. Next, we removed all non-CD8 cells from the data as well as cells labeled with antibody hashtag #1 (Biolegend 394661) in batch 3, which were used solely as carrier cells for the 10X reaction. Differentially expressed genes between clusters were found using the Seurat FindAllMarkers function with default parameters, and resolution parameter set to 0.5. Differentially expressed genes for 8 resulting clusters can be found in Supplementary Table 4. R

scripts for the final Seurat object generation can be found on GitHub (https://github.com/pogorely/COVID_vax_CD8).

Donor and epitope assignment using feature barcodes

Cells were processed in 3 batches (each batch making a separate 10x Chromium reaction). In each batch, each PBMC sample was uniquely labeled with a DNA-barcoded hashing antibody (TotalSeq-C anti-human Hashtag antibodies 1-10, Biolegend). We attributed a cell to a certain donor if more than 50% of UMIs derived from hashing antibodies were from the hashtag corresponding to that donor. Cells specific to certain dextramers were called similarly: we required more than 30% of dextramer-derived UMIs to contain a dextramer-specific barcode, and if multiple dextramers passed this threshold the cell was considered specific to both. If the most abundant dextramer barcode per cell was \leq 3 UMIs, we did not assign any epitope specificity to it. $TCR\alpha$ and $TCR\beta$ sequences were assembled from aggregated VDJ-enriched libraries using CellRanger (v. 6.0.0) vdj pipeline. For each cell we assigned the $TCR\beta$ and $TCR\alpha$ chain with the largest UMI count. The R script performing feature barcode deconvolution, GEX and TCR join is available on Github (https://github.com/pogorely/COVID_vax_CD8) as well as the resulting Supplementary Table 5.

TCR repertoire analysis

A T cell clone was defined as a group of cells from the same donor which have the same nucleotide sequences of both CDR3 α and CDR3 β (see Supplementary Table 6 for unique T cell clones). To measure the distance between TCR α/β clonotypes and plot logos for dominant motifs we used the TCRdist algorithm implementation and plotting functions from *conga* python package (Schattgen et al. 2020). TCR β repertoire diversity calculation was performed using normalized Shannon entropy $-(\sum_{i=1}^{n} p_i log_2(p_i))/log_2(n)$, where n is a total number of unique TCR β clonotypes, and pi is a frequency of i-th TCR β clonotype (defined as the fraction of cells with this TCR β of all cells in a sample with defined TCR β). Similarity network analysis and visualization were performed with the igraph R package (Csardi and Nepusz 2006) and gephi software (Jacomy et al. 2014).

Artificial antigen-presenting cells (aAPCs)

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

A gBlock gene fragment encoding full-length HLA-B*15:01 was synthesized by Genscript and cloned into the pLVX-EF1α-IRES-Puro lentiviral expression vector (Clontech). Lentivirus was generated by transfecting 293T packaging cell line (American Type Culture Collection (ATCC) CRL-3216) with the pLVX lentiviral vector containing the HLA-B*15:01 insert, psPAX2 packaging plasmid (Addgene plasmid #12260), and pMD2.G envelope plasmid (Addgene plasmid #12259). Viral supernatant was harvested and filtered 24- and 48-hours post-transfection, then concentrated using Lenti-X Concentrator (Clontech). K562 cells (ATCC CCL-243) were transduced, then antibiotic selected for one week using 2 μg/mL puromycin in Iscove's Modified Dulbecco's Medium (IMDM; Gibco) containing 10% FBS and 1% penicillin/streptomycin. Surface expression of HLA was confirmed via flow cytometry using antibodies against HLA-A, B, C (PE-conjugated, Biolegend 311406, clone W6/32).

TCR-expressing Jurkat 76.7 cells

TCRα (TRAV21, CAVHSSGTYKYIF, TRAJ40) and TCRβ (TRBV7-2, CASSLEDTNYGYTF, TRBJ1-2) chains matching both the biggest B15 NQK-specific motif on Fig 4B and prediction from (Minervina et al. 2021) were selected for Jurkat cell line generation. TCRα and TCRβ chains for the selected B15 NQK-specific TCR were modified to use murine constant regions (murine TRAC*01 and murine TRBC2*01). A gBlock gene fragment was synthesized by Genscript to encode the modified TCRα chain, the modified TCRβ chain, and mCherry, with all three genes linked together by 2A sites. This sequence was cloned into the pLVX-EF1α-IRES-Puro lentiviral expression vector (Clontech). Lentivirus was generated by transfecting 293T packaging cell line (ATCC CRL-3216) with the pLVX lentiviral vector containing the TCR-mCherry insert, psPAX2 packaging plasmid (Addgene plasmid #12260), and pMD2.G envelope plasmid (Addgene plasmid #12259). Viral supernatant was harvested and filtered 24- and 48-hours post-transfection, then concentrated using Lenti-X Concentrator (Clontech). Jurkat 76.7 cells (a gift from Wouter Scheper; variant of TCR-null Jurkat 76.7 cells that expresses human CD8 and an NFAT-GFP reporter) were transduced, then antibiotic selected for 1 week using 1 µg/mL puromycin in RPMI (Gibco) containing 10% FBS and 1% penicillin/streptomycin. Transduction was confirmed by expression of mCherry, and surface TCR expression was confirmed via flow cytometry using antibodies against mouse TCRβ constant region (PE-conjugated, Biolegend 109208, clone H57-597) and human CD3 (Brilliant Violet 785-conjugated, Biolegend 344842, clone SK7).

Intracellular cytokine staining functional assay

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

Jurkat 76.7 cells expressing the B15 NQK-specific TCR (2.5x10⁵) were cocultured with HLA-B*15:01 aAPCs (2.5x10⁵) pulsed with 1 μM of either NQKLIANAF peptide from HKU1/OC43 common cold coronaviruses or NOKLIANOF peptide from SARS-CoV2, 1 µg/mL each of antihuman CD28 (BD Biosciences 555725) and CD49d (BD Biosciences 555501), brefeldin A (GolgiPlug, 1 µL/mL; BD Biosciences 555029), and monensin (GolgiStop, 0.67 µL/mL; BD Biosciences 554724). An unstimulated (CD28, CD49d, brefeldin A, monensin) and positive control (brefeldin A, monensin, 1X Cell Stimulation Cocktail, PMA/ionomycin; eBioscience 00-4970-93) were included in each assay. Cells were incubated for 6 hours (37 °C, 5% CO-2). Following the 6-hour incubation, cells were washed twice with FACS buffer (PBS, 2% FBS, 1 mM EDTA), then blocked using human Fc-block (BD Biosciences 564220). Cells were then stained with 1 µL Ghost Dye Violet 510 Viability Dye (Tonbo Biosciences 13-0870-T100) and a cocktail of surface antibodies: 1 µL each of anti-human CD8 (Brilliant Violet 785-conjugated, Biolegend 344740, clone SK1), anti-human CD3 (Brilliant Violet 421-conjugated, Biolegend 344834, clone SK7), and anti-mouse TCRβ chain (PE-conjugated (Biolegend 109208) or APC/Fire750-conjugated (Biolegend 109246), clone H57-597). Cells were then washed twice with FACS buffer, then fixed and permeabilized using the Cytofix/Cytoperm Fixation/Permeabilization kit (BD Biosciences) according to the manufacturer's instructions. Following fixation and permeabilization, cells were washed twice with 1X Perm/Wash buffer and stained with a cocktail of intracellular antibodies: 1.25 µL of anti-human IFNy (Alexa Fluor 647-conjugated, Biolegend 502516, clone 4S.B3) and 1 μL anti-human CD69 (PerCP-eFluor710-conjugated, eBioscience 46-0699-42, clone FN50). Cells were then washed twice with 1X Perm/Wash buffer and analyzed by flow cytometry on a custom-configured BD Fortessa using FACSDiva software (Becton Dickinson). Flow cytometry data were analyzed using FlowJo software (TreeStar). Responsiveness to peptide stimulation was determined by measuring frequency of NFAT-GFP, IFNγ, and CD69 expression.

Tetramer generation and Jurkat Cell line staining

526 Biotinylated HLA-B*15-monomers loaded with NQKLIANQF (SARS-CoV-2) and

NQKLIANAF (CCCoV) versions of the peptide were tetramerised using TotalSeq-C-0951-PE-

Streptavidin (Biolegend 405261) and TotalSeq-C-0956-APC-Streptavidin (Biolegend 405283). 60

μL of HLA-monomers were mixed with 1 μL of PE-conjugated (for B15_NQKLIANQF) and

APC-conjugated for (B15_NQKLIANAF) streptavidin reagents and incubated for 1 hour in the

dark on ice. Jurkat 76.7 cells expressing the potentially cross-reactive TCR were stained with 1 μL

532 Ghost Dye Violet 510 Viability Dye (Tonbo Biosciences 13-0870-T100) and 5 μL of each MHC-

tetramer. Flow cytometry data were analyzed using FlowJo software (TreeStar). Cross-reactivity

of the Jurkat 76.7 T cell line was determined by co-staining of the live cells with PE and APC-

535 labeled MHC-tetramers.

525

527

528

529

530

531

533

534

536

537

539

540

544

545

547

550

551

552

553

554

555

Recombinant SARS-CoV-2 proteins and ELISA

Expression plasmids for the nucleocapsid (N) protein, spike protein, and the spike receptor binding

domain (RBD) from the Wuhan-Hu-1 isolate were obtained from Florian Krammer. Proteins were

transfected into Expi293F cells using a ExpiFectamine 293 transfection kit (Thermo Fisher

Scientific) as previously described (Amanat et al. 2020). Supernatants from transfected cells were

harvested and purified with a Ni-NTA column.

For hCoV and SARS-CoV-2 antibody detection, 384-well microtiter plates were coated overnight

at 4 °C, with recombinant proteins diluted in PBS. Optimal concentrations for each protein and

isotype were empirically determined to optimize sensitivity and specificity. SARS-CoV-2 spike

RBD was coated at 2 μg/mL in PBS. Full-length spike was coated at 2 μg/mL for IgG. N protein

was coated at 1 µg/mL. The spike proteins of hCoV-229E (Sino Biological, 40605-V08B), hCoV-

NL63 (Sino Biological, 40604-V08B), hCoV-HKU1 (Sino Biological, 40606-V08B), or hCoV-

OC43 (Sino Biological, 40607-V08B) were coated at 1 μg/mL for IgG detection. For all ELISAs,

plates were washed the next day three times with 0.1% PBS-T (0.1% Tween-20) and blocked with

3% OmniblokTM non-fat milk (AmericanBio; AB10109-01000) in PBS-T for one hour. Plates were

then washed, and incubated with plasma samples diluted 1:50 in 1% milk in PBS-T for 90 minutes

at room temperature. Prior to dilution, plasma samples were incubated at 56 °C for 15 minutes.

ELISA plates were washed and incubated for 30 minutes at room temperature with anti-human

secondary antibodies diluted in 1% milk in PBS-T: anti-IgG (1:10,000; Invitrogen, A18805). The

plates were washed and incubated at room temperature with OPD (Sigma-Alrich, P8287) for 10 minutes (for hCoV ELISAs) or SIGMAFAST OPD (Sigma-Alrich; P9187) for 8 minutes (for SARS-CoV-2 ELISAs) and absorbances were measured at 490 nm on a microplate reader. To ensure the specificity of this assay, we first screened samples from a prior study that included young children to identify samples to serve as negative controls. In addition, as a control for plate-to-plate variability, we selected two positive samples from the SJTRC cohort that were tested on each plate and used to calculate the percent ratio, which is the OD of each sample relative to the OD of the control samples. Samples with a percent ratio greater than three times the average of the negative controls were considered positive for the hCoV and two times the average of the negative controls for the SARS-CoV-2 antigens. Antibody levels for each donor can be found in the Supplementary Table 2.

Statistical analysis

556

557

558

559

560

561

562

563

564

565

566

567

568

572

573

578

579

- 569 Statistical analysis was performed in R version 4.0.3. Wilcoxon signed-rank test was used to
- 570 compare paired pre-vaccination and post-vaccination samples, Wilcoxon rank-sum test was used
- to compare unpaired samples between study groups.

Data and code availability

- 574 Code required to reproduce source data for figures is available on GitHub:
- 575 https://github.com/pogorely/COVID vax CD8. All data produced in the study is available as
- 576 supplementary files. Raw sequencing data was deposited to Short Read Archive acc.
- 577 PRJNA744851.

Acknowledgements

- We thank all the donors who volunteered for the SJTRC study, Phil Bradley and Stefan Schattgen
- 581 for their consultations on TCR dist and conga algorithms, Greig Lennon from St. Jude Immunology
- flow core for his help with FACS, and Hartwell Center for high-throughput sequencing. This work
- was funded by ALSAC at St. Jude, the Center for Influenza Vaccine Research for High-Risk
- Populations (CIVR-HRP) contract number 75N93019C00052 (S.S-C, P.G.T), the St. Jude Center
- 585 of Excellence for Influenza Research and Surveillance (S.S-C, M.A.M, P.G.T),

- 586 HHSN272201400006C, 3U01AI144616-02S1 (P.G.T, M.A.M, S.S-C), and R01AI136514
- 587 (P.G.T).

597

601

- 589 Author Contributions
- 590 Conceptualization: A.A.M, M.V.P, E.K.A, J.C.C. and P.G.T. Formal analysis: A.A.M, M.V.P,
- 591 A.M.K, J.C.C, M.A.M, J.W, J.H.E, X.Z, K.V, G.W. Investigation: A.A.M., M.V.P, A.M.K,
- 592 M.A.M, J.W, J.E., C-Y.L, D.B. Methods development: A.A.M, M.V.P, A.M.K, C-Y.L, S.S-C,
- 593 M.A.M. Resources: S.S-C, M.A.M, P.T, J.H.E., J.W. Data and sample curation: J.W, J.H.E, E.K.A,
- 594 K.J.A, SJTRC Study Team. Writing, original draft: A.A.M. and M.V.P. Writing, review, and
- editing: A.A.M, M.V.P, A.M.K, E.K.A, J.C.C, J.W, M.A.M, P.G.T. Visualization: A.A.M.
- 596 Supervision: P.G.T. Funding Acquisition: P.G.T.
- 598 Competing interests
- P.G.T has consulted or received honorarium and travel support from Illumina and 10X. P.G.T.
- serves on the Scientific Advisory Board of Immunoscape and Cytoagents.
- **Supplementary information**
- 603 Supplementary Table 1. SARS-CoV-2 derived CD8+ epitopes used for MHC-multimer
- 604 generation.
- 605 Supplementary Table 2. Study participants metadata.
- **Supplementary Table 3.** Mutations in studied epitopes from SARS-CoV-2 variants.
- 607 Supplementary Table 4. Differentially expressed genes for GEX clusters of epitope-specific
- 608 CD8+ T cells.
- 609 Supplementary Table 5. Epitope-specific CD8+ T cells GEX clusters, TCR and epitope
- 610 specificity.

612

Supplementary Table 6. Unique epitope-specific CD8+ αβTCR clonotypes.





Fig 1. Measuring CD8+ T cell epitope-specific responses in SARS-CoV-2 naive and recovered individuals after mRNA vaccination. a. Study design. Left: Peripheral blood samples SARS-CoV-2 naive donors (n=9) and SARS-CoV-2 recovered donors (n=10) were collected after 2 doses of Pfizer/BioNtech vaccine. For SARS-CoV-2 recovered donors, we collected another sample at a previous timepoint before (purple, "post-infection") or after vaccination (pink, "post-vax"). Time of blood sampling for each donor is shown relative to the first dose of vaccine. Right: Selected spike and non-spike SARS-CoV-2 T cell epitopes were loaded on recombinant biotinylated MHC-monomers. Resulting peptide-MHC complexes were polymerized using fluorescently-labeled and DNA-barcoded dextran backbones. Next, we stained PBMC samples with pools of MHC-multimers, isolated bound cells using FACS, and performed scRNAseq, scTCRseq, and CITEseq using the 10X Genomics platform. b. Anti-RBD IgG antibody levels in SARS-CoV-2 recovered individuals increase after immunization with Pfizer-BioNTech BNT162b2 (p=0.016, Wilcoxon signed-rank test). Inset: after two doses of vaccine anti-RBD IgG levels are the same for SARS-CoV-2 naive donors (green) and SARS-CoV-2 recovered donors (blue) (p=0.18, Wilcoxon rank-sum test) and both are larger than post-infection levels in SARS-CoV-2 recovered donors (purple).

- **c.** List of SARS-CoV-2 epitopes used in this study. Table shows peptide sequences, source proteins, and summary statistics for resulting epitope-specific responses (number of HLA-matched samples with a response and number of epitope-specific cells recovered from scRNAseq).
- d. Total frequency of MHC-dextramer-positive cells is similar in SARS-CoV-2 recovered individuals post-infection (purple) and post-vaccination (blue), and in SARS-CoV-2 naive donors post-vaccination (green). Percentage of MHC-multimer-positive cells from all CD8+ T cells measured by flow cytometry is shown on a log-scale.



638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653 654


655

656

657

658

Figure 2. Magnitude, dynamics, and cross-reactivity of CD8+ epitope-specific responses to SARS-CoV-2 infection and vaccination, a. Antigen specificity of each T cell could be inferred from dextramer-barcode UMI counts. Representative distribution of the number of UMIs in cells called dextramer-positive (pink) and dextramer-negative (vellow), b. T cells within a clone have consistent specificity assignments, except T cells that cross-react with common cold coronavirus epitopes (B15 NOK A/B15 NOK O pair). Each bar shows a fraction of cells of a given clonotype attributed to different dextramers. The 15 most abundant clones (more than 12 cells) are shown. c. The same cells bind both SARS-CoV-2 and CCCoV variants of the HLA-B*15:01-restricted spike-derived (NOKLIANA|OF) epitope. Number of UMIs for B15 NOK Q (SARS-CoV-2) and B15 NOK A (OC43 and HKU1) dextramers are correlated (Spearman p=0.65, p<0.001). d. Cross-reactivity between HLA-B*15:01-NOK epitope variants confirmed in vitro. Jurkat cell line expressing αβTCR identified from scTCRseq data binds pMHC multimers loaded with both SARS-CoV-2 and CCCoV variants of epitope. e. A01 TTD, A01 LTD, A02 YLO, B15 NOK epitopes elicit strongest T cell responses. Each point is an estimated frequency of epitope-specific T cells in a sample. Estimated frequency was calculated as a fraction of dextramer-specific T cells in scRNAseq results multiplied by bulk frequency of dextramerstained CD8+ cells of all CD8+ cells measured by flow cytometry. f. Estimated frequency of spikespecific T cells are comparable between experimental groups (right). A02 YLQ tends to elicit a stronger response in the context of vaccination (left). g. Boosting of spike-specific epitope fraction after immunization (donor R6). Each colored ribbon represents an estimated frequency of spike- (purple) or non-spike- (blue) specific T cell clones. h. SARS-CoV-2 recovered individuals have a higher proportion of spike-specific T cells after vaccination than before vaccination. The fraction of spike-specific T cells out of all epitope-specific T cells is plotted for paired post-infection and post-vaccination timepoints of COVID-19 recovered donors (p=0.047, Wilcoxon signed-rank test).



661 662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

Figure 3. Phenotypic diversity of epitope-specific CD8 T cells after natural SARS-CoV-2 infection and vaccination, a. UMAP (Uniform manifold approximation and projection) of all SARS-CoV-2 epitope-specific CD8 T cells based on gene expression (GEX). Color shows results of graph-based unsupervised clustering performed with the Seurat package. b. Density plot of CCR7 and CD45RA surface expression (measured by CITE-seq) in GEX clusters. c. Bubble plot of representative differentially expressed genes for each cluster. Size of the circle shows percentage of cells in a cluster expressing a certain gene, color scale shows gene expression level. d. Distribution of spike-specific (top subpanel) and non-spike-specific (bottom subpanel) T cells in gene expression clusters between study groups. Colors show corresponding clusters from a, b. e. Proportion of spike-specific T cells is significantly increased in EMRA cluster (cluster 1, green on d) after vaccination of SARS-CoV-2 recovered individuals, compared to the pre-vaccination timepoint (p=0.007, one-tailed Wilcoxon rank-sum test). f. Clone size distribution within GEX clusters. Fractions of cells from 10 most abundant clonotypes in each cluster are shown with colors, all other clonotypes are shown in grey. Clusters 4, 6, and in particular 2 have the most expanded clones. g. Number of cells in cluster 2 (Exhausted) and cluster 6 (Cycling) in samples are strongly correlated (Spearman p=0.8, p<0.001). Shaded area shows 95% confidence interval for linear fit. h. UMAP of spike-specific (bottom subpanel) and non-spike-specific (top subpanel) T cells sampled at two different timepoints from the same individuals based on GEX. Cluster 2 of exhausted T cells and cluster 6 of cycling T cells disappear at the later timepoint irrespective of T cell specificity (spike or non-spike). i. Distribution of cells from the largest observed clone between GEX clusters 7 days after the second dose (transparent dots) and 54 days after the second dose (opaque dots). Although the vast majority of cells from exhausted cluster 2 (purple) disappear, the clone persists in memory subpopulations. i. Vaccination of COVID-19 recovered does not affect spike-specific T cell repertoire diversity. Normalized Shannon entropy of TCRβ is plotted for samples with more than 3 unique TCRβ clonotypes.




Figure 4. Both SARS-CoV-2 infection and vaccination activate diverse polyclonal repertoire of epitope-specific T cells with distinctive sequence motifs. a. SARS-CoV-2 epitope-specific αβTCR amino acid clonotypes feature clusters of highly similar sequences with the same epitope specificity. Each node on a similarity network is a unique paired αβTCR amino acid sequence, and an edge connects αβTCRs with TCRdist less than 120. Each color represents a certain epitope specificity. Clonotypes without neighbors are not shown. b. TCR amino acid sequence motifs of α and β chains (TCRdist logos) for the largest clusters of highly similar TCRs for each epitope (circled with dashed line on A). c. TCRs with the same sequence motifs are found both after natural infection, and post-vaccination of both naive and recovered subjects in a matching HLA-background. Occurrence of TCR motifs on the left is shown for all HLA matching and non-matching samples (rectangles on the plot). Grey rectangles represent samples lacking the TCR motif. The color of the rectangle that has a TCR motif corresponds to the sample group (purple for post-infection, pink, and blue for post-vaccination of recovered individuals, green for post-vaccination of naive individuals).




Fig. S1. Subject selection for the study. a. Time after second vaccination does not differ between recovered and immunologically naive groups. b. HLA-type distribution is similar across study groups.




Fig. S2. Antibody levels across study groups. IgG levels to the receptor-binding domain (RBD) of the spike (left) and whole spike (middle) of SARS-CoV are boosted in recovered donors after vaccination (IgG RBD: p=0.016; IgG spike: p=0.016, Wilcoxon signed-rank test). Recovered donors after immunization have similar RBD IgG antibody levels (p=1, Wilcoxon rank-sum test), and even higher spike IgG (p=0.026, Wilcoxon rank-sum test) in comparison to SARS-CoV-2-naive vaccinated group. SARS-CoV-2 naive individuals are negative for N-specific IgG. Purple line on the plots indicates the positivity threshold.




Fig. S3. Gating strategy for sorting of single live CD3+CD8+dextramer+ cells.




Fig S4. Dextramer assignment with feature barcodes. Each subplot shows distribution of Log₁₀ (# UMIs) for dextramers with certain feature barcodes in dextramer-negative (yellow) and dextramer-positive (pink) cells.




Fig. S5. Peptide stimulation confirms cross-reactivity of B15_NQK αβTCR. From left to right: unstimulated (negative control), NQKLIANQF (SARS-CoV-2) peptide stimulation, NQKLIANAF (OC43 and HKU1) peptide stimulation, PMA/Ionomycin (positive control). Top row: IFNgamma production by TCR-expressing Jurkats measured by intracellular cytokine staining. Middle row: CD69+ surface expression. Bottom row: NFAT-GFP reporter expression.




Fig S6. Antibody titers for CCCoV spike protein (HKU1 left panel, OC43 middle panel) and number of B15-NQF/NAF cross-reactive cells in HLA*B15:01+ donors (right panel, log-scale). Donor N1 has low levels of IgG anti-CCCoV antibodies and T cells cross-reactive with CCCoV derived HLA*B15:01-restricted epitope.




Fig. S7. Clonal dynamics of spike and non-spike specific T cell response for each donor between two timepoints. Each colored ribbon represents an estimated frequency of spike- (purple) or non-spike- (blue) specific T cell clones. **a.** Recovered donors (R1-R6), that have timepoint 1 sampled after the infection and timepoint 2 sampled after second dose of the vaccine. **b.** Recovered donors (R7, R8, R10), that have timepoint 1 sampled after the first dose of the vaccine and timepoint 2 sampled after the second dose of the vaccine. **c.** Recovered donor (R9), that have timepoint 1 sampled 7 days after the second dose of the vaccine and timepoint 2 sampled 54 days after second dose of the vaccine.




Fig. S8. GEX cluster distribution for each sample. Each coloured bar represents a fraction of cells in a given GEX cluster. See Fig. 3 a, b for UMAP and cluster identities (the colour code for clusters is consistent between figures).




Fig. S9. UMAP visualization of cells clustered by similarity of GEX. Each subpanel shows cells from donors sampled at a given timepoint.




Fig. S10. "Exhausted" cluster 2 (circled) is enriched with cells from expanded clones. The color of each dot shows the size of the T cell clone (Log₁₀ of number of cells) for each cell.




Fig. S11. VJ-usage for immunodominant epitopes. Height of each rectangle corresponds to the fraction of unique epitope-specific T cell clones expressing a given V- or J-segment in the $TCR\alpha$ (a) and $TCR\beta$ (b) chain. Ribbons show the frequency of VJ combinations.

750




Fig. S12. $V\alpha$ - $V\beta$ pairings for immunodominant epitopes. Height of each rectangle corresponds to the fraction of unique epitope-specific T cell clones expressing a given TRAV or TRBV-segment. Ribbons show frequencies of TRAV-TRBV combinations.

757 References 758 Amanat, Fatima, Daniel Stadlbauer, Shirin Strohmeier, Thi H. O. Nguyen, Veronika 759 Chromikova, Meagan McMahon, Kaijun Jiang, et al. 2020. "A Serological Assay to 760 Detect SARS-CoV-2 Seroconversion in Humans." Nature Medicine 26 (7): 1033–36. 761 https://doi.org/10.1038/s41591-020-0913-5. 762 Camara, Carmen, Daniel Lozano-Ojalvo, Eduardo Lopez-Granados, Estela Paz-Artal, Marjorie 763 Pion, Rafael Correa-Rocha, Alberto Ortiz, et al. 2021. "Differential Effects of the Second 764 SARS-CoV-2 MRNA Vaccine Dose on T Cell Immunity in Naïve and COVID-19 Recovered Individuals." Preprint. Immunology. 765 766 https://doi.org/10.1101/2021.03.22.436441. 767 Cornberg, Markus, Alex T. Chen, Lee A. Wilkinson, Michael A. Brehm, Sung-Kwon Kim, 768 Claudia Calcagno, Dario Ghersi, et al. 2006. "Narrowed TCR Repertoire and Viral Escape as a Consequence of Heterologous Immunity." The Journal of Clinical 769 770 Investigation 116 (5): 1443–56. https://doi.org/10.1172/JCI27804. 771 Csardi, Gabor, and Tamas Nepusz. 2006. "The Igraph Software Package for Complex Network Research." InterJournal Complex Systems: 1695. 772 773 Cukalac, Tania, Jesseka Chadderton, Andreas Handel, Peter C. Doherty, Stephen J. Turner, Paul 774 G. Thomas, and Nicole L. La Gruta. 2014. "Reproducible Selection of High Avidity 775 CD8+ T-Cell Clones Following Secondary Acute Virus Infection." Proceedings of the 776 National Academy of Sciences of the United States of America 111 (4): 1485–90. 777 https://doi.org/10.1073/pnas.1323736111. 778 Cukalac, Tania, Jessica M. Moffat, Vanessa Venturi, Miles P. Davenport, Peter C. Doherty, 779 Stephen J. Turner, and John Stambas. 2009. "Narrowed TCR Diversity for Immunised 780 Mice Challenged with Recombinant Influenza A-HIV Env(311-320) Virus." Vaccine 27 781 (48): 6755–61. https://doi.org/10.1016/j.vaccine.2009.08.079. 782 Dash, Pradyot, Andrew J. Fiore-Gartland, Tomer Hertz, George C. Wang, Shalini Sharma, Aisha 783 Souquette, Jeremy Chase Crawford, et al. 2017. "Quantifiable Predictive Features Define 784 Epitope-Specific T Cell Receptor Repertoires." *Nature* 547 (7661): 89–93. 785 https://doi.org/10.1038/nature22383. 786 Diao, Bo, Chenhui Wang, Yingjun Tan, Xiewan Chen, Ying Liu, Lifen Ning, Li Chen, et al. 787 2020. "Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus

Disease 2019 (COVID-19)." Frontiers in Immunology 11 (May): 827. 788 789 https://doi.org/10.3389/fimmu.2020.00827. 790 Ebinger, Joseph E., Justyna Fert-Bober, Ignat Printsey, Min Wu, Nancy Sun, John C. Prostko, 791 Edwin C. Frias, et al. 2021. "Antibody Responses to the BNT162b2 MRNA Vaccine in 792 Individuals Previously Infected with SARS-CoV-2." Nature Medicine 27 (6): 981–84. 793 https://doi.org/10.1038/s41591-021-01325-6. Ferretti, Andrew P., Tomasz Kula, Yifan Wang, Dalena M.V. Nguyen, Adam Weinheimer, 794 795 Garrett S. Dunlap, Qikai Xu, et al. 2020. "Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 That Largely Reside 796 797 Outside the Spike Protein." Immunity 53 (5): 1095-1107.e3. 798 https://doi.org/10.1016/j.immuni.2020.10.006. 799 Francis, Joshua M., Del Leistritz-Edwards, Augustine Dunn, Christina Tarr, Jesse Lehman, 800 Conor Dempsey, Andrew Hamel, et al. 2021. "Allelic Variation in Class I HLA 801 Determines Pre-Existing Memory Responses to SARS-CoV-2 That Shape the CD8 + T 802 Cell Repertoire upon Viral Exposure." Preprint. Immunology. 803 https://doi.org/10.1101/2021.04.29.441258. 804 Gangaev, Anastasia, Steven L. C. Ketelaars, Olga I. Isaeva, Sanne Patiwael, Anna Dopler, Kelly 805 Hoefakker, Sara De Biasi, et al. 2021. "Identification and Characterization of a SARS-806 CoV-2 Specific CD8+ T Cell Response with Immunodominant Features." Nature 807 Communications 12 (1): 2593. https://doi.org/10.1038/s41467-021-22811-y. 808 Glanville, Jacob, Huang Huang, Allison Nau, Olivia Hatton, Lisa E. Wagar, Florian Rubelt, 809 Xuhuai Ji, et al. 2017. "Identifying Specificity Groups in the T Cell Receptor 810 Repertoire." *Nature* 547 (7661): 94–98. https://doi.org/10.1038/nature22976. 811 Goel, Rishi R., Sokratis A. Apostolidis, Mark M. Painter, Divij Mathew, Ajinkya Pattekar, Oliva 812 Kuthuru, Sigrid Gouma, et al. 2021. "Distinct Antibody and Memory B Cell Responses 813 in SARS-CoV-2 Naïve and Recovered Individuals Following MRNA Vaccination." 814 Science Immunology 6 (58): eabi6950. https://doi.org/10.1126/sciimmunol.abi6950. 815 Habel, Jennifer R., Thi H. O. Nguyen, Carolien E. van de Sandt, Jennifer A. Juno, Priyanka 816 Chaurasia, Kathleen Wragg, Marios Koutsakos, et al. 2020. "Suboptimal SARS-CoV-817 2-specific CD8 + T Cell Response Associated with the Prominent HLA-A*02:01 818 Phenotype." *Proceedings of the National Academy of Sciences* 117 (39): 24384–91.

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840 841

842

843

844

845

846

847

848

849

https://doi.org/10.1073/pnas.2015486117. Harris, Paul A., Robert Taylor, Brenda L. Minor, Veida Elliott, Michelle Fernandez, Lindsay O'Neal, Laura McLeod, et al. 2019. "The REDCap Consortium: Building an International Community of Software Platform Partners." Journal of Biomedical Informatics 95 (July): 103208. https://doi.org/10.1016/j.jbi.2019.103208. Harris, Paul A., Robert Taylor, Robert Thielke, Jonathon Payne, Nathaniel Gonzalez, and Jose G. Conde. 2009. "Research Electronic Data Capture (REDCap)—A Metadata-Driven Methodology and Workflow Process for Providing Translational Research Informatics Support." *Journal of Biomedical Informatics* 42 (2): 377–81. https://doi.org/10.1016/j.jbi.2008.08.010. Jacomy, Mathieu, Tommaso Venturini, Sebastien Heymann, and Mathieu Bastian. 2014. "ForceAtlas2, a Continuous Graph Layout Algorithm for Handy Network Visualization Designed for the Gephi Software." Edited by Mark R. Muldoon. *PLoS ONE* 9 (6): e98679. https://doi.org/10.1371/journal.pone.0098679. Kared, Hassen, Andrew D. Redd, Evan M. Bloch, Tania S. Bonny, Hermi Sumatoh, Faris Kairi, Daniel Carbajo, et al. 2021. "SARS-CoV-2-Specific CD8+ T Cell Responses in Convalescent COVID-19 Individuals." *Journal of Clinical Investigation* 131 (5): e145476. https://doi.org/10.1172/JCI145476. Krammer, Florian, Komal Srivastava, Hala Alshammary, Angela A. Amoako, Mahmoud H. Awawda, Katherine F. Beach, Maria C. Bermúdez-González, et al. 2021. "Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 MRNA Vaccine." New England Journal of Medicine 384 (14): 1372–74. https://doi.org/10.1056/NEJMc2101667. Kusnadi, Anthony, Ciro Ramírez-Suástegui, Vicente Fajardo, Serena J Chee, Benjamin J Meckiff, Hayley Simon, Emanuela Pelosi, et al. 2021. "Severely Ill COVID-19 Patients Display Impaired Exhaustion Features in SARS-CoV-2-Reactive CD8 ⁺ T Cells." Science *Immunology* 6 (55): eabe4782. https://doi.org/10.1126/sciimmunol.abe4782. Malherbe, Laurent, Linda Mark, Nicolas Fazilleau, Louise J. McHeyzer-Williams, and Michael G. McHeyzer-Williams. 2008. "Vaccine Adjuvants Alter TCR-Based Selection Thresholds." *Immunity* 28 (5): 698–709. https://doi.org/10.1016/j.immuni.2008.03.014. Mazzoni, Alessio, Nicoletta Di Lauria, Laura Maggi, Lorenzo Salvati, Anna Vanni, Manuela

850 Capone, Giulia Lamacchia, et al. 2021. "First-Dose MRNA Vaccination Is Sufficient to 851 Reactivate Immunological Memory to SARS-CoV-2 in Subjects Who Have Recovered 852 from COVID-19." Journal of Clinical Investigation 131 (12): e149150. 853 https://doi.org/10.1172/JCI149150. 854 Minervina, Anastasia A, Ekaterina A Komech, Aleksei Titov, Meriem Bensouda Koraichi, Elisa 855 Rosati, Ilgar Z Mamedov, Andre Franke, et al. 2021. "Longitudinal High-Throughput 856 TCR Repertoire Profiling Reveals the Dynamics of T-Cell Memory Formation after Mild 857 COVID-19 Infection." ELife 10 (January): e63502. https://doi.org/10.7554/eLife.63502. 858 Nelde, Annika, Tatjana Bilich, Jonas S. Heitmann, Yacine Maringer, Helmut R. Salih, Malte 859 Roerden, Maren Lübke, et al. 2021. "SARS-CoV-2-Derived Peptides Define 860 Heterologous and COVID-19-Induced T Cell Recognition." *Nature Immunology* 22 (1): 861 74–85. https://doi.org/10.1038/s41590-020-00808-x. 862 Nguyen, Thi H.O., Louise C. Rowntree, Jan Petersen, Brendon Y. Chua, Luca Hensen, Lukasz 863 Kedzierski, Carolien E. van de Sandt, et al. 2021. "CD8+ T Cells Specific for an 864 Immunodominant SARS-CoV-2 Nucleocapsid Epitope Display High Naive Precursor 865 Frequency and TCR Promiscuity." Immunity 54 (5): 1066-1082.e5. https://doi.org/10.1016/j.immuni.2021.04.009. 866 Nielsen, Stine SF, Line K Vibholm, Ida Monrad, Rikke Olesen, Giacomo S Frattari, Marie H 867 868 Pahus, Jesper F Højen, et al. 2021. "SARS-CoV-2 Elicits Robust Adaptive Immune 869 Responses Regardless of Disease Severity." EBioMedicine 68 (June): 103410. 870 https://doi.org/10.1016/j.ebiom.2021.103410. 871 Oberle, Susanne G., Layane Hanna-El-Daher, Vijaykumar Chennupati, Sarah Enouz, Stefanie 872 Scherer, Martin Prlic, and Dietmar Zehn. 2016. "A Minimum Epitope Overlap between 873 Infections Strongly Narrows the Emerging T Cell Repertoire." Cell Reports 17 (3): 627– 874 35. https://doi.org/10.1016/j.celrep.2016.09.072. 875 Painter, Mark M., Divij Mathew, Rishi R. Goel, Sokratis A. Apostolidis, Ajinkya Pattekar, Oliva 876 Kuthuru, Amy E. Baxter, et al. 2021. "Rapid Induction of Antigen-Specific CD4 + T 877 Cells Guides Coordinated Humoral and Cellular Immune Responses to SARS-CoV-2 878 MRNA Vaccination." Preprint. Immunology. https://doi.org/10.1101/2021.04.21.440862. 879 Peng, Yanchun, Alexander J. Mentzer, Guihai Liu, Xuan Yao, Zixi Yin, Danning Dong, 880 Wanwisa Dejnirattisai, et al. 2020. "Broad and Strong Memory CD4+ and CD8+ T Cells

881 Induced by SARS-CoV-2 in UK Convalescent Individuals Following COVID-19." 882 *Nature Immunology* 21 (11): 1336–45. https://doi.org/10.1038/s41590-020-0782-6. 883 Petrie, Joshua G., and Arnold S. Monto. 2017. "Untangling the Effects of Prior Vaccination on 884 Subsequent Influenza Vaccine Effectiveness." The Journal of Infectious Diseases 215 885 (6): 841–43. https://doi.org/10.1093/infdis/jix056. 886 Reynisson, Birkir, Bruno Alvarez, Sinu Paul, Bjoern Peters, and Morten Nielsen. 2020. 887 "NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved Predictions of MHC Antigen 888 Presentation by Concurrent Motif Deconvolution and Integration of MS MHC Eluted Ligand Data." Nucleic Acids Research 48 (W1): W449–54. 889 890 https://doi.org/10.1093/nar/gkaa379. 891 Rha, Min-Seok, Hye Won Jeong, Jae-Hoon Ko, Seong Jin Choi, In-Ho Seo, Jeong Seok Lee, 892 Moa Sa, et al. 2021. "PD-1-Expressing SARS-CoV-2-Specific CD8+ T Cells Are Not 893 Exhausted, but Functional in Patients with COVID-19." *Immunity* 54 (1): 44-52.e3. 894 https://doi.org/10.1016/j.immuni.2020.12.002. 895 Robinson, James, Dominic J Barker, Xenia Georgiou, Michael A Cooper, Paul Flicek, and Steven G E Marsh. 2019. "IPD-IMGT/HLA Database." Nucleic Acids Research, October, 896 897 gkz950. https://doi.org/10.1093/nar/gkz950. 898 Sahin, Ugur, Alexander Muik, Evelyna Derhovanessian, Isabel Vogler, Lena M. Kranz, Mathias 899 Vormehr, Alina Baum, et al. 2020. "COVID-19 Vaccine BNT162b1 Elicits Human 900 Antibody and TH1 T Cell Responses." *Nature* 586 (7830): 594–99. 901 https://doi.org/10.1038/s41586-020-2814-7. 902 Sahin, Ugur, Alexander Muik, Isabel Vogler, Evelyna Derhovanessian, Lena M. Kranz, Mathias 903 Vormehr, Jasmin Quandt, et al. 2021. "BNT162b2 Vaccine Induces Neutralizing 904 Antibodies and Poly-Specific T Cells in Humans." Nature, May. 905 https://doi.org/10.1038/s41586-021-03653-6. 906 Saini, Sunil Kumar, Ditte Stampe Hersby, Tripti Tamhane, Helle Rus Povlsen, Susana Patricia 907 Amaya Hernandez, Morten Nielsen, Anne Ortved Gang, and Sine Reker Hadrup. 2021. 908 "SARS-CoV-2 Genome-Wide T Cell Epitope Mapping Reveals Immunodominance and 909 Substantial CD8 + T Cell Activation in COVID-19 Patients." Science Immunology 6 (58): 910 eabf7550. https://doi.org/10.1126/sciimmunol.abf7550. 911 Schattgen, Stefan A., Kate Guion, Jeremy Chase Crawford, Aisha Souquette, Alvaro Martinez

912 Barrio, Michael J.T. Stubbington, Paul G. Thomas, and Philip Bradley. 2020. "Linking T 913 Cell Receptor Sequence to Transcriptional Profiles with Clonotype Neighbor Graph 914 Analysis (CoNGA)." Preprint. Immunology. https://doi.org/10.1101/2020.06.04.134536. 915 Schreibing, Felix, Monica Hannani, Fabio Ticconi, Eleanor Fewings, James S Nagai, Matthias 916 Begemann, Christoph Kuppe, et al. 2021. "Dissecting CD8+ T Cell Pathology of Severe 917 SARS-CoV-2 Infection by Single-Cell Epitope Mapping." Preprint. Immunology. 918 https://doi.org/10.1101/2021.03.03.432690. Schulien, Isabel, Janine Kemming, Valerie Oberhardt, Katharina Wild, Lea M. Seidel, Saskia 919 920 Killmer, Sagar, et al. 2021. "Characterization of Pre-Existing and Induced SARS-CoV-2-921 Specific CD8+ T Cells." Nature Medicine 27 (1): 78-85. https://doi.org/10.1038/s41591-020-01143-2. 922 923 Sekine, Takuya, André Perez-Potti, Olga Rivera-Ballesteros, Kristoffer Strålin, Jean-Baptiste 924 Gorin, Annika Olsson, Sian Llewellyn-Lacey, et al. 2020. "Robust T Cell Immunity in 925 Convalescent Individuals with Asymptomatic or Mild COVID-19." Cell 183 (1): 158-926 168.e14. https://doi.org/10.1016/j.cell.2020.08.017. 927 Shomuradova, Alina S., Murad S. Vagida, Savely A. Sheetikov, Ksenia V. Zornikova, Dmitry 928 Kiryukhin, Aleksei Titov, Iuliia O. Peshkova, et al. 2020. "SARS-CoV-2 Epitopes Are 929 Recognized by a Public and Diverse Repertoire of Human T Cell Receptors." Immunity 930 53 (6): 1245-1257.e5. https://doi.org/10.1016/j.immuni.2020.11.004. 931 Snyder, Thomas M., Rachel M. Gittelman, Mark Klinger, Damon H. May, Edward J. Osborne, 932 Ruth Taniguchi, H. Jabran Zahid, et al. 2020. "Magnitude and Dynamics of the T-Cell 933 Response to SARS-CoV-2 Infection at Both Individual and Population Levels." Preprint. 934 Infectious Diseases (except HIV/AIDS). https://doi.org/10.1101/2020.07.31.20165647. 935 Stuart, Tim, Andrew Butler, Paul Hoffman, Christoph Hafemeister, Efthymia Papalexi, William 936 M. Mauck, Yuhan Hao, Marlon Stoeckius, Peter Smibert, and Rahul Satija. 2019. 937 "Comprehensive Integration of Single-Cell Data." Cell 177 (7): 1888-1902.e21. 938 https://doi.org/10.1016/j.cell.2019.05.031. 939 Tarke, Alison, John Sidney, Conner K. Kidd, Jennifer M. Dan, Sydney I. Ramirez, Esther Dawen 940 Yu, Jose Mateus, et al. 2021. "Comprehensive Analysis of T Cell Immunodominance and 941 Immunoprevalence of SARS-CoV-2 Epitopes in COVID-19 Cases." Cell Reports 942 Medicine 2 (2): 100204. https://doi.org/10.1016/j.xcrm.2021.100204.

943 Thevarajan, Irani, Thi H. O. Nguyen, Marios Koutsakos, Julian Druce, Leon Caly, Carolien E. 944 van de Sandt, Xiaoxiao Jia, et al. 2020. "Breadth of Concomitant Immune Responses 945 Prior to Patient Recovery: A Case Report of Non-Severe COVID-19." Nature Medicine 26 (4): 453–55. https://doi.org/10.1038/s41591-020-0819-2. 946 947 Thimme, Robert, Valerie Oberhardt, Hendrik Luxenburger, Janine Kemming, Isabel Schulien, 948 Kevin Ciminski, Sebastian Giese, et al. 2021. "Rapid and Stable Mobilization of Fully 949 Functional Spike-Specific CD8+ T Cells Preceding a Mature Humoral Response after 950 SARS-CoV-2 MRNA Vaccination." Preprint. In Review. https://doi.org/10.21203/rs.3.rs-951 505193/v1. 952 Wang, Zijun, Frauke Muecksch, Dennis Schaefer-Babajew, Shlomo Finkin, Charlotte Viant, 953 Christian Gaebler, Hans- Heinrich Hoffmann, et al. 2021. "Naturally Enhanced 954 Neutralizing Breadth against SARS-CoV-2 One Year after Infection." Nature, June. 955 https://doi.org/10.1038/s41586-021-03696-9. 956 Zheng, Hong-Yi, Mi Zhang, Cui-Xian Yang, Nian Zhang, Xi-Cheng Wang, Xin-Ping Yang, 957 Xing-Qi Dong, and Yong-Tang Zheng. 2020. "Elevated Exhaustion Levels and Reduced 958 Functional Diversity of T Cells in Peripheral Blood May Predict Severe Progression in COVID-19 Patients." Cellular & Molecular Immunology 17 (5): 541–43. 959 960 https://doi.org/10.1038/s41423-020-0401-3. 961 962 963 964